Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 20 versus CYLERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 20 versus CYLERT.
ADDERALL 20 vs CYLERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
CNS stimulant; increases extracellular dopamine and norepinephrine levels by blocking their reuptake and enhancing release.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
37.5 mg orally once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day.
None Documented
None Documented
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Terminal elimination half-life is 12-30 hours in children (mean 19 hours) and 8-14 hours in adults; the long half-life supports once-daily dosing, but accumulation can occur with repeated dosing
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Primarily renal (80-90% as unchanged drug and metabolites, with 50-60% as unchanged pemoline), minor biliary/fecal elimination (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant